Roche plans to market its experimental breast cancer pill giredestrant under the brand name Wilserdly, Bloomberg reported, citing unnamed people familiar with the matter. The Swiss drugmaker has already lodged the name with trademark authorities in several territories while it waits to learn whether regulators will clear the drug.

The first regulatory verdict arrives soon. The U.S. Food and Drug Administration has awarded priority status to two giredestrant filings, with a decision on the first — covering early-stage breast cancer — due Nov. 30. A decision on the second, for use with everolimus in advanced disease, is expected in December.

Why the name Wilserdly?

The brand name encodes the drug's mechanism, according to Bloomberg. It contains "SERD," the acronym for selective estrogen receptor degraders — a class of medicines that break down a receptor which breast tumors can rely on to fuel their growth.

Genentech, Roche's U.S. subsidiary, sought a trademark on Oct. 27, filing the name in block capitals alongside a floral logo. Roche has filed for the identical name with other trademark bodies around the globe, including the European Union Intellectual Property Office. Regulators must approve a drug's name before it reaches patients; Roche declined to comment on the filings.

How is Roche preparing for launch?

Roche is getting ready to bring giredestrant to the American market the moment it receives the green light, according to Bloomberg. The launch would include a patient-support program for women starting treatment.

The commercial stakes center on being first. Oral SERDs have already won approval for more limited groups of advanced breast cancer patients, among them:

• Menarini Group's Orserdu
• Eli Lilly's (LLY) Inluriyo

Roche aims to reach the market first for the broader population of early-stage patients, ahead of AstraZeneca's (AZN) Etcamah.

What about Europe?

The European timeline runs years behind the U.S. Roche intends to apply for European approval in 2027, after additional evidence — such as overall survival results — becomes available, according to Bloomberg.

Pricing negotiations could delay the launch there. If Roche and European payers fail to strike deals, the drug might launch late or remain unavailable in certain European markets.

What happens next?

Two FDA decisions — Nov. 30 and December — will determine whether the trademark filings convert into a commercial product in the United States. Approval of the early-stage indication would position Wilserdly as the first oral SERD for that broader patient population, ahead of AstraZeneca's competing candidate. A European filing would follow in 2027, contingent on survival data.